VX18-445-104: A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Comination Therapy in Subject with Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation